Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia

J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.

Abstract

Over the last months, pandemic SARS‐CoV‐2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS‐CoV‐2 infection with associated clinical improvements. We report herein a case series of patients with COVID‐19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes.

This article is protected by copyright. All rights reserved.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19* / drug therapy
  • Humans
  • Off-Label Use
  • SARS-CoV-2*

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab

Supplementary concepts

  • COVID-19 drug treatment